Will the first patient receive a pig kidney in eGenesis's RESTORE trial by June 30, 2027?

Five people have received eGenesis gene edited pig kidneys under Expanded Access since March 2024, and one passed nine months off dialysis. The FDA cleared a 33 patient Phase 1/2/3 trial called RESTORE, which the company expects to start in the first quarter of 2027.

How this question entered the record and how it will be resolved.

Resolution criteria

Resolves Yes if eGenesis or Mass General Brigham publicly announces, on or before June 30, 2027, that a patient received an EGEN-2784 kidney transplant as part of the RESTORE trial. Transplants under Expanded Access do not count. Resolves No otherwise.

Expected resolution

Jun 30, 2027

• eGenesis press release, September 3, 2026: FDA cleared RESTORE for 33 patients, start expected in the first quarter of 2027
• The Lancet, September 3, 2026: first report of a patient bridged from a pig kidney to a human kidney transplant

Starting a trial is different from the first surgery, which depends on finding eligible, matched patients aged 50 to 70 and on pig supply.

• Outcomes for the Expanded Access patients still on study
• Any FDA hold on xenotransplant trials